• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Healthcare·DASA3.SA
Share

Diagnosticos da America S.A. Stocks

R$ 2.79Last Updated 01.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

R$ 672.15M

R$ 2.79
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Diagnósticos da América S.A., together with its subsidiaries, provides diagnostic and hospital services in Brazil and Argentina. The company operates through Hospitals and Oncology; Diagnostics - National Operations; and Diagnostics - International Operations segments. It also offers medical, property and vehicle rental, consultancy, and franchise contracting services. The company was formerly known as Laboratório Clínico Delboni Auriemo S.A. and changed its name to Diagnósticos da América S.A. in August 2000. Diagnósticos da América S.A. was founded in 1961 and is headquartered in São Paulo, Brazil.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, undervalued on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of DASA3.SA is 4.4 and suggests 55.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

02.07.2026 22:40

Mizuho has added a company with 125% growth potential to its top picks. Who is the new favorite?

02.07.2026 22:08

Blue Owl reported a decline in investor requests to withdraw assets. Its stock rose

02.07.2026 21:30

Freedom expects a correction in the tech sector in July. But it won't last long.

02.07.2026 21:14

"Palantir's valuation is currently the most attractive": Analyst Predicts 39% Stock Gain

02.07.2026 19:23

Freedom Broker has removed Apple and 11 other stocks from its top picks. Who has taken their place?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026